Format

Send to:

Choose Destination
See comment in PubMed Commons below
Emerg Infect Dis. 2005 Mar;11(3):411-6.

Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.

Author information

  • 1Wohl Virion Centre and Division of Infection and Immunity, University College London, 46 Cleveland St, London W1T 4JF, London, UK. nigel.temperton@ucl.ac.uk

Abstract

The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay that is both sensitive and specific for SARS-CoV neutralizing antibodies. Neutralization titers measured by this assay are highly correlated to those measured by an assay using replication-competent SARS-CoV. No cross-neutralization occurred with human sera known to contain antibodies to coronavirus strains OC43 and 229E. The pseudotype assay was used to profile neutralizing antibody responses against SARS-CoV S in sequential serum samples taken from 41 confirmed SARS patients during the 2003 outbreak in Hong Kong and shows long-lasting immunity in most recovered patients. The pseudotype assay does not require handling live SARS virus; it is a useful tool to determine neutralizing titers during natural infection and the preclinical evaluation of candidate vaccines.

PMID:
15757556
[PubMed - indexed for MEDLINE]
PMCID:
PMC3298259
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for CDC-NCEZID Icon for PubMed Central
    Loading ...
    Write to the Help Desk